MOBIN VARGHESE: Open Payments
NPI 1114504248 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,306 in 54 payments from 17 companies in 2025. Trend: 2023 $1,200 · 2024 $1,479 · 2025 $1,306
Food & beverage: $1,306
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 10 | $267 |
| Amgen Inc. | 6 | $141 |
| Novo Nordisk Inc | 6 | $137 |
| Veloxis Pharmaceuticals, Inc. | 4 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| Travere Therapeutics, Inc. | 4 | $98 |
| Mallinckrodt Hospital Products Inc. | 4 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $74 |
| AstraZeneca Pharmaceuticals LP | 3 | $62 |
| KYOWA KIRIN, INC. | 2 | $47 |
Products named: PREVYMIS, KRYSTEXXA, ENVARSUS, LIVTENCITY, JARDIANCE, ACTHAR, FARXIGA, Ozempic.
Industry payments across TX — which companies pay providers there.
